$CYCC
Cyclacel Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013351 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.054M $1.580M $1.605M
YoY Change 15.33% -20.96% -7.71%
% of Gross Profit
Research & Development $4.413M $4.205M $4.954M
YoY Change 4.65% 2.54% 93.06%
% of Gross Profit
Depreciation & Amortization $7.000K $8.000K $9.000K
YoY Change -30.0% -52.94% 0.0%
% of Gross Profit
Operating Expenses $6.467M $5.785M $6.559M
YoY Change 7.82% -5.16% 52.36%
Operating Profit -$6.467M -$5.785M -$6.559M
YoY Change 7.82% -5.16% 52.36%
Interest Expense $343.0K $226.0K $33.00K
YoY Change 2538.46% -2611.11% 135.71%
% of Operating Profit
Other Income/Expense, Net $357.0K $226.0K $1.313M
YoY Change 2646.15% 2411.11% 837.86%
Pretax Income -$6.110M -$5.559M -$5.246M
YoY Change 2.09% -8.73% 25.95%
Income Tax -$1.014M -$984.0K -$1.138M
% Of Pretax Income
Net Earnings -$5.096M -$4.575M -$4.108M
YoY Change 2.19% -10.77% 18.11%
Net Earnings / Revenue
Basic Earnings Per Share -$0.42 -$0.46 -$0.42
Diluted Earnings Per Share -$0.42 -$0.46 -$0.42
COMMON SHARES
Basic Shares Outstanding 12.54M 10.14M 9.993M
Diluted Shares Outstanding 12.31M 10.14M 9.993M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.71M $29.08M $29.64M
YoY Change -41.06% -33.37% -37.96%
Cash & Equivalents $23.70M $29.10M $29.60M
Short-Term Investments
Other Short-Term Assets $170.0K $79.00K $1.539M
YoY Change 51.79% -44.37% 127.66%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.92M $32.08M $36.58M
YoY Change -35.64% -30.57% -27.52%
LONG-TERM ASSETS
Property, Plant & Equipment $37.00K $48.00K $57.00K
YoY Change -47.89% -34.25% -95.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.916M $3.060M $2.980M
YoY Change 93.24%
Total Long-Term Assets $3.106M $3.269M $3.052M
YoY Change 91.26% 2395.42% 125.41%
TOTAL ASSETS
Total Short-Term Assets $27.92M $32.08M $36.58M
Total Long-Term Assets $3.106M $3.269M $3.052M
Total Assets $31.02M $35.35M $39.63M
YoY Change -31.06% -23.71% -23.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $983.0K $2.205M $2.850M
YoY Change -35.12% 84.21% 227.21%
Accrued Expenses $3.370M $2.821M $3.354M
YoY Change 62.33% 46.85% 123.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.353M $5.026M $6.204M
YoY Change 21.22% 61.19% 123.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $107.0K $113.0K $15.00K
YoY Change 143.18% -98.49%
Total Long-Term Liabilities $107.0K $113.0K $15.00K
YoY Change 143.18% -98.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.353M $5.026M $6.204M
Total Long-Term Liabilities $107.0K $113.0K $15.00K
Total Liabilities $4.460M $5.139M $6.219M
YoY Change 22.7% 64.82% 65.05%
SHAREHOLDERS EQUITY
Retained Earnings -$398.7M -$393.6M -$389.1M
YoY Change 5.02% 5.06%
Common Stock $9.000K $11.00K $10.00K
YoY Change -10.0% 22.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.07M $30.21M $33.41M
YoY Change
Total Liabilities & Shareholders Equity $31.02M $35.35M $39.63M
YoY Change -31.06% -23.71% -23.52%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$5.096M -$4.575M -$4.108M
YoY Change 2.19% -10.77% 18.11%
Depreciation, Depletion And Amortization $7.000K $8.000K $9.000K
YoY Change -30.0% -52.94% 0.0%
Cash From Operating Activities -$6.968M -$1.915M -$6.775M
YoY Change 12.21% -54.57% 89.99%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$3.000K $4.000K
YoY Change -100.0% -104.84% -94.87%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$3.000K -$4.000K
YoY Change -100.0% -104.84% -94.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.532M 1.474M -50.00K
YoY Change -47.25% -2990.2% -100.28%
NET CHANGE
Cash From Operating Activities -6.968M -1.915M -6.775M
Cash From Investing Activities 0.000 -3.000K -4.000K
Cash From Financing Activities 1.532M 1.474M -50.00K
Net Change In Cash -5.436M -444.0K -6.920M
YoY Change 63.98% -89.44% -148.15%
FREE CASH FLOW
Cash From Operating Activities -$6.968M -$1.915M -$6.775M
Capital Expenditures $0.00 -$3.000K $4.000K
Free Cash Flow -$6.968M -$1.912M -$6.779M
YoY Change 12.37% -55.3% 86.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10136089
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9234110
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10065007
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8172472
dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11350289
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9993135
dei Entity Central Index Key
EntityCentralIndexKey
0001130166
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50626
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4575000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5127000
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
517-7330
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12539189
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29077000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36559000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3000000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4383000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
32077000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
40942000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30000
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3060000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1551000
CY2022Q2 us-gaap Assets
Assets
35346000
CY2021Q4 us-gaap Assets
Assets
42587000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2205000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2117000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2821000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3177000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5026000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5294000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30000
CY2022Q2 us-gaap Liabilities
Liabilities
5139000
CY2021Q4 us-gaap Liabilities
Liabilities
5324000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11350289
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9993135
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
425114000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422960000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1276000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-748000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393642000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384959000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30207000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35346000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42587000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4205000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4101000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9159000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6667000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1580000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1999000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3185000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3738000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5785000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
6100000
us-gaap Operating Expenses
OperatingExpenses
12344000
us-gaap Operating Expenses
OperatingExpenses
10405000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5785000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6100000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12344000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10405000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
209000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
238000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
17000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
us-gaap Investment Income Interest
InvestmentIncomeInterest
21000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
18000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1280000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
144000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
226000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1539000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
149000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5559000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6091000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10805000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10256000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-984000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-964000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2122000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1651000
us-gaap Net Income Loss
NetIncomeLoss
-8683000
us-gaap Net Income Loss
NetIncomeLoss
-8605000
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
CY2021Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
101000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
101000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4625000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5177000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8784000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8706000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10136089
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9234110
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10065007
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8172472
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4575000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5127000
us-gaap Net Income Loss
NetIncomeLoss
-8683000
us-gaap Net Income Loss
NetIncomeLoss
-8605000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15715000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-869000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21518000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2452000
CY2022Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-16168000
CY2021Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
941000
cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-22046000
cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
2540000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5028000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5055000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9211000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8517000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
33259000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13502000
CY2021Q1 cycc Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
4545000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
255000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2021Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
1599000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1583000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3478000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
48049000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2021Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
941000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-869000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5127000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
43216000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
380000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2022Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-5878000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5803000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4108000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33410000
CY2022Q2 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
1525000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2022Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-16168000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15715000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4575000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30207000
us-gaap Net Income Loss
NetIncomeLoss
-8683000
us-gaap Net Income Loss
NetIncomeLoss
-8605000
us-gaap Depreciation
Depreciation
17000
us-gaap Depreciation
Depreciation
26000
us-gaap Share Based Compensation
ShareBasedCompensation
730000
us-gaap Share Based Compensation
ShareBasedCompensation
533000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
115000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
926000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
476000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
172000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
626000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8690000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7781000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16000
cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
1525000
cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
18047000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
101000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
101000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1424000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17946000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-209000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7482000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10233000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33406000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29077000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43639000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
21000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
9000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
3328000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1390000
cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29100000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6161543
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5161550
CY2022Q2 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
2000000
CY2021Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
3727000
CY2022Q2 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
921000
CY2021Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
577000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
79000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
79000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3000000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4383000
CY2022Q2 cycc Deposits Held By Related Party
DepositsHeldByRelatedParty
3100000
CY2022Q2 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1896000
CY2021Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2310000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
233000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
558000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
634000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2821000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3177000
us-gaap Operating Lease Expense
OperatingLeaseExpense
30470
us-gaap Operating Lease Expense
OperatingLeaseExpense
144463
us-gaap Operating Lease Payments
OperatingLeasePayments
30870
us-gaap Operating Lease Payments
OperatingLeasePayments
150941
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
31000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
65000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2022Q2 cycc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
197000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
350000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
278000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
730000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
533000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
0001558370-22-013351-index-headers.html Edgar Link pending
0001558370-22-013351-index.html Edgar Link pending
0001558370-22-013351.txt Edgar Link pending
0001558370-22-013351-xbrl.zip Edgar Link pending
cycc-20220630.xsd Edgar Link pending
cycc-20220630x10q.htm Edgar Link pending
cycc-20220630xex31d1.htm Edgar Link pending
cycc-20220630xex31d2.htm Edgar Link pending
cycc-20220630xex32d1.htm Edgar Link pending
cycc-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
cycc-20220630_def.xml Edgar Link unprocessable
cycc-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cycc-20220630_pre.xml Edgar Link unprocessable
cycc-20220630x10q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cycc-20220630_cal.xml Edgar Link unprocessable